Abstract Objective To analyze the efficacy and safety of Capecitabine maintenance in elderly patients with advanced triple negative breast cancer. Methods A total of 100 elderly patients with advanced triple negative breast cancer treated in Shangrao People′s Hospital from July 2016 to July 2019 were selected as the research objects, and were divided into control group (50 cases) and observation group (50 cases) by random number table method. The control group was treated with Docetaxel+Doxorubicin+Cyclophosphamide, the observation group was additionally given Capecitabine maintenance therapy. Treatment effect, progression-free survival, median survival and total incidence of adverse reactions were compared between the two groups. Results The total effective rate of the observation group was 88.00%, higher than that of the control group 64.00%, the difference was statistically significant (P<0.05). The progression-free survival and median survival in the observation group were (7.26±1.42) and (21.32±2.33) months, respectively, longer than (5.62±1.52) and (16.59±2.31) months in the control group, the differences were statistically significant (P<0.05). The total incidence of adverse reactions in the observation group was 4.00%, lower than 18.00% in the control group, the difference was statistically significant (P<0.05). Conclusion Capecitabine maintenance therapy can effectively prolong the survival of patients, improve the treatment effect, significantly improve the prognosis of patients, and high safety, less adverse reactions, worthy of promotion.
YU Meijian,TAN Jinlong,CHEN Zhigang. Efficacy and safety of Capecitabine maintenance in elderly patients with advanced triple negative breast cancer[J]. 中国当代医药, 2022, 29(20): 92-94.
Garrido-Castro AC，Lin NU，Polyak K.Insights into Molecular Classifications of Triple-Negative Breast Cancer：Improving Patient Selection for Treatment[J].Cancer Discov，2019，9（2）：176-198.
